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Background
Tacrolimus (Tac) is the mainstay of standard immunosup-
pressive regime in renal transplantation today. However, it
needs regular drug level monitoring in view of narrow
therapeutic window to keep blood level in therapeutic
range. The objective of the study was to assess the poten-
tial influence of a functional polymorphism in CYP3A5*3
gene on dose requirements and trough blood levels of
tacrolimus in renal transplant patients
Materials & methods
This prospective observational study included 20
patients of end stage renal disease who underwent renal
transplantion and a follow up of 1 year at our hospital.
All the patients were started on standard immunosuppres-
sive regime of Tacrolimus-Mycophenolate mofetil along
with steroids with a starting dose of Tac 0.08 mg/kg/day.
Genotype of CYP3A5 was studied in 20 patients requiring
low dose of Tac. At 7th and 30th day, and 3 monthly after
transplant, Tac dosages (mg/kg/d), were adjusted based on
blood levels and complications. Polymerase chain reaction,
followed by restriction fragment length polymorphism
analysis was used for genotyping CYP3A5*3 gene
(A6986G) in intron 3.
Results
Out of 20 patients (17 males and 3 females) included in
the study, 16 had live related renal transplantation and
4 had diseased donor renal transplantation. Out of
20 patients 16 were found to have CYP3A5 homozygous
status (A3986G polymorphism in CYP3A5*3 gene-wild
allele) and 4 with heterozygous status. Patients of CYP3A5
homozygous status had mean Tac level of 16.84 ng/dL,
median of 15.5 ng/dL (range- 13.2-25 ng/dL) on 7th day of
transplant. So Tac dose was reduced to achieve TDL and
mean Tac level at 30th day of transplant was 6.6 ng/dL
and median of 7.4 ng/dL (range- 5.5-12.5 ng/dL). At 6th
month and 12th month of transplant, mean Tac levels
were 6.1 ng/dL and 5.9 ng/dL. In patients having CYP3A5
homozygous status, mean and median Tac dose after 4
weeks was 0.03 mg/kg/day (range- 0.008 to 0.05 mg/kg/
day) and mean creatinine was 1.17 mg/dL (range-0.8 to
1.4 mg/dL) after 30th day. Remaining 4 patients having
CYP3A5 heterozygous status were maintaining TDL at
Tac dose of 0.06 mg/kg/day. Five patients had graft biopsy
during first 4 weeks of renal transplant showing acute
tubular necrosis (ATN) in three patients, acute cellular
rejection in one patient and cellular rejection with evidence
of calcineurine inhibitor (CNI) toxicity in one patient.
Conclusion
This study demonstrates the usefulness of CYP3A5
genotype in transplant patients taking Tacrolimus-
Mycophenolate mofetil and also shows that majority of our
patients carry mutant allele A3986G in CYP3A5*3 gene.
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